Content about Acquisition

April 23, 2012

Par Pharmaceutical has bought rights to a generic drug for gastroesophageal reflux disease from Handa Pharmaceuticals, Par said.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical has bought rights to a generic drug for gastroesophageal reflux disease from Handa Pharmaceuticals, Par said.

Handa, based in Fremont, Calif., sold rights to the regulatory approval application it filed with the Food and Drug Administration for dexlansoprazole capsules, a generic version of Takeda's Dexilant, in the 60-mg strength.

April 13, 2012

The Body Shop, which was acquired by L’Oréal in 2006, is looking to revamp its 2,700 global stores to its new store concept, dubbed “Pulse,” according to published reports.

The Body Shop, which was acquired by L’Oréal in 2006, is looking to revamp its 2,700 global stores to its new store concept, dubbed “Pulse,” according to published reports. The first Pulse Boutique opened in March in London on Oxford Street, according to reports. 


April 11, 2012

Takeda Pharmaceutical will acquire privately owned drug maker URL Pharma for $800 million, the companies said Wednesday.

DEERFIELD, Ill. — Takeda Pharmaceutical will acquire privately owned drug maker URL Pharma for $800 million, the companies said Wednesday.

Takeda announced that it would acquire Philadelphia-based URL through a U.S. subsidiary for the upfront payment plus future milestone payments. Takeda said it expected the acquisition to contribute "significantly" to its sales and profits starting in fiscal year 2013.

April 10, 2012

Biotech manufacturer Amgen will acquire the private South San Francisco, Calif.-based drug developer Kai Pharmaceuticals for $315 million, the companies said Tuesday.

THOUSAND OAKS, Calif. — Biotech manufacturer Amgen will acquire the private South San Francisco, Calif.-based drug developer Kai Pharmaceuticals for $315 million, the companies said Tuesday.

The deal includes the acquisition of KAI-4169, an experimental drug Kai is developing for secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. Amgen has provided a loan to fund phase-3 clinical studies of the drug and will acquire rights to it worldwide, except for Japan.

April 9, 2012

Sensible Organics, a maker of organic personal care products and one of the first beauty care companies to receive the U.S. Department of Agriculture national organic certification, has announced that it will launch its Nourish Organic Food for Healthy Skin brand at Whole Foods stores nationwide.

AUSTIN, Texas — Sensible Organics, a maker of organic personal care products and one of the first beauty care companies to receive the U.S. Department of Agriculture national organic certification, has announced that it will launch its Nourish Organic Food for Healthy Skin brand at Whole Foods stores nationwide.


Nourish is among the first personal care brands to offer 100% USDA certified organic formulations offered in distinctive scents made of The Nourish collection scents include fresh fig, almond vanilla, lavender mint and wild berries. 


April 6, 2012

Par Pharmaceutical has started shipping its generic version of a drug for sleep disorders, the company said Friday.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical has started shipping its generic version of a drug for sleep disorders, the company said Friday.

Par announced the launch of a generic version of Provigil (modafinil), used to treat such sleep disorders as narcolepsy and work shift sleep disorder.

April 3, 2012

Forest Labs has bought rights to a drug used for high blood pressure that it had marketed with a Johnson & Johnson subsidiary, thus eliminating the need to pay future royalties.

NEW YORK — Forest Labs has bought rights to a drug used for high blood pressure that it had marketed with a Johnson & Johnson subsidiary, thus eliminating the need to pay future royalties.

Forest announced Monday that it had bought all U.S. and Canadian intellectual property related to Bystolic (nebivolol) for $357 million from Janssen Pharmaceutica NV on Friday.

April 2, 2012

A leading provider of immune support products has become part of Schiff Nutrition.

SALT LAKE CITY — A leading provider of immune support products has become part of Schiff Nutrition.

Schiff announced that it acquired Friday the Airborne brand GF Capital Private Equity Fund LP in an all-cash transaction valued at $150 million, subject to certain adjustments. The company said the acquisition positions Schiff as a leader in the immune support segment.

March 30, 2012

Teva Pharmaceutical Industries has launched an authorized generic version of Cephalon's Provigil, used for conditions like shift work sleep disorder and narcolepsy, the company said Friday.

JERUSALEM — Teva Pharmaceutical Industries has launched an authorized generic version of Cephalon's Provigil, used for conditions like shift work sleep disorder and narcolepsy, the company said Friday.

Teva acquired Cephalon for $6.8 billion in October 2011. An authorized generic is the branded drug marketed under its generic name at a reduced price.

Provigil had annual sales of about $1.1 billion, according to IMS Health.

 

March 27, 2012

Hyperion Therapeutics has purchased rights to a drug for treating genetic metabolic disorders, the company said.

SOUTH SAN FRANCISCO, Calif. — Hyperion Therapeutics has purchased rights to a drug for treating genetic metabolic disorders, the company said.

Hyperion announced the purchase of Ravicti (glycerol phenylbutyrate) from Ucyclyd Pharma, a subsidiary of Medicis Pharmaceutical.

March 23, 2012

Former Walgreens' CEO Jeff Rein said profit pressure might cause Walgreens to think differently about acquisitions than it did in the past.

WHAT IT MEANS AND WHY IT'S IMPORTANT — Former Walgreens' CEO Jeff Rein said profit pressure might cause Walgreens to think differently about acquisitions than it did in the past. The loss of Express Scripts patients (who are incidentally taking their prescriptions to the nearest Walgreens competitor), coupled with a significant generic wave through 2012 — moreso in the back half of the year — potentially could keep Walgreens from posting a profit through fiscal 2012. "Walgreens is in a real poor position here," Rein said.

March 19, 2012

Walgreens might be willing to acquire Rite Aid if it can't settle an ongoing contractual dispute with one of the country's largest pharmacy benefit managers, Walgreens' former CEO said in a conference call with investors Monday.

NEW YORK — Walgreens might be willing to acquire Rite Aid if it can't settle an ongoing contractual dispute with one of the country's largest pharmacy benefit managers, Walgreens' former CEO said in a conference call with investors Monday.

Interviewed by Credit Suisse analyst Edward Kelly, former Walgreens CEO Jeff Rein suggested that Walgreens' board "would have the stomach" to buy Rite Aid if it doesn't reach an agreement with Express Scripts, as buying Rite Aid's nearly 4,700 stores would give Walgreens considerable leverage against the PBM.

March 6, 2012

AmerisourceBergen on Tuesday announced that it has signed a definitive agreement to purchase World Courier Group, a privately held global specialty transportation and logistics provider for the biopharmaceutical industry, for $520 million in cash.

VALLEY FORGE, Pa. — AmerisourceBergen on Tuesday announced that it has signed a definitive agreement to purchase World Courier Group, a privately held global specialty transportation and logistics provider for the biopharmaceutical industry, for $520 million in cash.

February 22, 2012

Novartis plans to pay up to $440 million for rights to a drug for treating hepatitis C made by Enanta Pharmaceuticals, Enanta said.

WATERTOWN, Mass. — Novartis plans to pay up to $440 million for rights to a drug for treating hepatitis C made by Enanta Pharmaceuticals, Enanta said.

Enanta said it had made a licensing agreement with the Swiss drug maker for the worldwide development, manufacturing and commercialization of the drug EDP-239, which works by inhibiting NS5A, a protein that is key to the virus' replication.

February 21, 2012

A division of Pfizer is asserting that it incurred nearly $1 billion in damages related to the launch of generic versions of one of its drugs.

MUMBAI, India — A division of Pfizer is asserting that it incurred nearly $1 billion in damages related to the launch of generic versions of one of its drugs.

In a lawsuit filed in the U.S. District Court for the District of New Jersey against Sun Pharmaceutical Industries and Teva Pharmaceutical Industries, Wyeth Pharmaceuticals said it estimated that it suffered damages of $960 million from Sun's and Teva's launches of generic versions of the gastroesophageal reflux disease drug Protonix (pantoprazole).

February 17, 2012

One of the main plotlines of the big story called the drug industry over the past several years has been the patent cliff, the steady loss of patent protection on blockbuster primary care drugs and subsequent generic competition that has forced many drug companies to find new revenue streams.

One of the main plotlines of the big story called the drug industry over the past several years has been the patent cliff, the steady loss of patent protection on blockbuster primary care drugs and subsequent generic competition that has forced many drug companies to find new revenue streams. Much of this has taken place in the form of a gradual shift to specialty drugs for such conditions as cancers and autoimmune disorders, but recent developments have shown that primary care drugs may still have some steam left in them.


February 15, 2012

Kellogg's is fortifying its snacks business by purchasing Procter & Gamble's Pringles business for nearly $2.7 billion.

BATTLE CREEK, Mich. — Kellogg's is fortifying its snacks business by purchasing Procter & Gamble's Pringles business for nearly $2.7 billion.

The companies expect to complete the transaction in the summer of 2012, pending necessary regulatory approvals.

The announcement follows last year's agreement between P&G and Diamond Foods through which Diamond Foods would acquire Pringles for $2.35 billion. The deal was delayed "to allow Diamond Foods to complete an accounting investigation."

February 13, 2012

Valeant Pharmaceuticals is set to acquire a privately owned ophthalmic biotechnology company, the drug maker said Monday.

MISSISSAUGA, Ontario — Valeant Pharmaceuticals is set to acquire a privately owned ophthalmic biotechnology company, the drug maker said Monday.

Valeant said it will acquire Eyetech upfront payment and potential future milestones. The transaction, which is subject to customary closing conditions, is expected to close this week. Additional details were not disclosed.

February 6, 2012

Mylan has completed its acquisition of two skin drugs from Valeant Pharmaceuticals, the generic drug maker said Monday.

PITTSBURGH — Mylan has completed its acquisition of two skin drugs from Valeant Pharmaceuticals, the generic drug maker said Monday.

Mylan announced that it had acquired the regulatory approval applications for generic clindamycin phosphate and benzoyl peroxide gel, a generic version of Valeant's BenzaClin, and a license to manufacture and market fluorouracil cream in the 5% strength, a version of Valeant's Efudex.

February 2, 2012

Acosta Sales and Marketing on Wednesday announced it has completed the acquisition of Griffin Strategic Advisors and will form a new business unit called AMG Strategic Advisors.

JACKSONVILLE, Fla. — Acosta Sales and Marketing on Wednesday announced it has completed the acquisition of Griffin Strategic Advisors and will form a new business unit called AMG Strategic Advisors.

February 1, 2012

Ever wonder how the convenient care industry blossomed into what it is today? One could say a fortune cookie.

Ever wonder how the convenient care industry blossomed into what it is today? One could say a fortune cookie.

“I love Chinese food, and my kids always get me Chinese food for dinner on Mother’s Day. My Chinese fortune cookie said, when I opened [it]: ‘You will be offered the opportunity of a lifetime, say yes,’” explained Sandy Ryan, Walgreens’ Take Care Health Systems chief nurse practitioner officer and clinical advocate.

January 26, 2012

Drug maker Amgen is acquiring a Rockville, Md.-based company developing therapies for cancer, the companies said Thursday.

THOUSAND OAKS, Calif. — Drug maker Amgen is acquiring a Rockville, Md.-based company developing therapies for cancer, the companies said Thursday.

Amgen announced plans to buy Micromet for $1.16 billion, or $11 per share. Micromet, originally founded in Germany, is developing blinatumomab, currently in phase-2 trials as a treatment for acute lymphoblastic leukemia and non-Hodgkin's lymphoma. The acquisition also will include the company's research and development center in Munich.

January 11, 2012

PZ Cussons, a consumer products group in Europe, Asia and Africa, is expanding its beauty division with the acquisition of the Fudge hair care brand from Australia-based Sabre Group.

LONDON — PZ Cussons, a consumer products group in Europe, Asia and Africa, is expanding its beauty division with the acquisition of the Fudge hair care brand from Australia-based Sabre Group.

The brand and associated inventory are being acquired by PZ Cussons for 25.5 million pounds ($39.5 million). The transaction is expected to close by the end of January, following the satisfaction of certain regulatory obligations.

January 9, 2012

Bristol-Myers Squibb is buying Inhibitex for $2.5 billion, the companies said.

NEW YORK — Bristol-Myers Squibb is buying Inhibitex for $2.5 billion, the companies said.

In a $26-per-share tender offer, Bristol will acquire the Alpharetta, Ga.-based developer of treatments for hepatitis C. Inhibitex's lead product is INX-189, an orally administered drug currently in phase-2 clinical trials.

December 23, 2011

In an effort to focus on its digital growth initiatives and accelerate its transformation to a digital company, Eastman Kodak said it is selling its Eastman Gelatine business to Rousselot, which is part of the Vion Food Group.

ROCHESTER, N.Y. — In an effort to focus on its digital growth initiatives and accelerate its transformation to a digital company, Eastman Kodak said it is selling its Eastman Gelatine business to Rousselot, which is part of the Vion Food Group.